Skip to main content

Table 4 Prospective evaluation of the EGFR status of exons 19 and 21

From: Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

% of tumoral

tumoral samples (n = 206)

EGFR mutations (n = 18)

 

cells

number

%

exon 19

exon 21

%

<20%

36

17.5

0

1

2.8

from 20 to 50%

98

47.6

3

6

9.2

>50%

72

35

5

3

11.1

  1. Samples may contain at least 20% of tumor cells to allow a correct detection of mutations
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us